Mead Johnson Nutrition Company is one of the leading providers of nutritional products for infants, children and expectant and nursing mothers. Its Enfa franchise that includes Enfamil infant formula accounts for almost 80% of the company’s net sales.
Currently, Mead Johnson has a Zacks Rank #4 (Sell) but that could change following its third-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate stands at 86 cents per share for past 7 days. Mead Johnson’s adjusted earnings per share of 87 cents missing this estimate by a penny.
Revenues: Mead Johnson posted revenues of $937.5 million, almost in line with the Zacks Consensus Estimate for revenues of $938 million.
Key Stats: Revenue from Asia decreased 3% to $463.2 million, while sales from Latin America dropped 19% y/y to $160.6 million. On the other hand, sales from North America/Europe dropped 1% y/y to $313.7 million.
Major Factors: Per management, despite facing near-term challenges, Mead Johnson made good progress with its portfolio and channel transformation in China. Currently the company aims at implementing more ambitious operating cost reductions. The company’s overall cash structure remains strong.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Mead Johnson earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Image: Bigstock
Mead Johnson Nutrition (MJN) Q3: Sales Met, Earnings Missed
Mead Johnson Nutrition Company is one of the leading providers of nutritional products for infants, children and expectant and nursing mothers. Its Enfa franchise that includes Enfamil infant formula accounts for almost 80% of the company’s net sales.
Currently, Mead Johnson has a Zacks Rank #4 (Sell) but that could change following its third-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate stands at 86 cents per share for past 7 days. Mead Johnson’s adjusted earnings per share of 87 cents missing this estimate by a penny.
GNC HOLDINGS Price and EPS Surprise
GNC HOLDINGS Price and EPS Surprise | GNC HOLDINGS Quote
Revenues: Mead Johnson posted revenues of $937.5 million, almost in line with the Zacks Consensus Estimate for revenues of $938 million.
Key Stats: Revenue from Asia decreased 3% to $463.2 million, while sales from Latin America dropped 19% y/y to $160.6 million. On the other hand, sales from North America/Europe dropped 1% y/y to $313.7 million.
Major Factors: Per management, despite facing near-term challenges, Mead Johnson made good progress with its portfolio and channel transformation in China. Currently the company aims at implementing more ambitious operating cost reductions. The company’s overall cash structure remains strong.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Mead Johnson earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>